Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-08-13 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' (External Investment Management System) of 海创药业股份有限公司 (Haichuang Pharmaceutical Co., Ltd.) dated August 2025. It is a detailed internal policy document outlining the company's procedures, approval authorities, organizational structure, financial management, auditing, and information disclosure related to external investments. It includes chapters on approval limits, management responsibilities, financial and audit controls, and reporting obligations. There is no indication that this is a financial report, earnings release, or regulatory filing. It is a governance-related document detailing internal rules and procedures for managing external investments. Therefore, it fits best under Governance Information (CGR). The document length (7474 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2025-08-13 Chinese
中信证券股份有限公司关于海创药业股份有限公司变更部分募集资金投资项目的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding adjustments to the investment projects funded by the proceeds from the initial public offering (IPO) of Haichuang Pharmaceutical Co., Ltd. It discusses the use and reallocation of raised funds, approvals by the board and shareholders, and compliance with regulatory requirements. The document includes financial figures related to the investment projects but does not present a full financial report or comprehensive financial statements. It is a regulatory compliance and verification report related to fundraising and use of proceeds, not an annual or interim financial report, earnings release, or capital change announcement. The document length is 4506 characters, which is relatively short but contains substantive content about fundraising project adjustments and regulatory compliance. This fits best under the category of Capital/Financing Update (CAP), as it updates on the use and adjustment of capital raised through the IPO and related investment projects.
2025-08-13 Chinese
关于首次公开发行股票部分募投项目子项目调整的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding adjustments to the sub-projects of its initial public offering (IPO) fundraising investment projects. It details changes in the use of raised funds, approvals by the board and supervisory committees, and the need for shareholder meeting approval. The document includes financial figures related to the fundraising and investment projects but does not contain comprehensive financial statements or detailed financial performance data. It is primarily an update on capital use and project adjustments related to the IPO proceeds. This fits the definition of a Capital/Financing Update (CAP) rather than a full Annual Report, Interim Report, or other financial report. The document length is about 5,037 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-08-13 Chinese
会计师事务所选聘制度
Governance Information Classification · 95% confidence The document is titled '海创药业股份有限公司 会计师事务所选聘制度' which translates to 'Hai Chuang Pharmaceutical Co., Ltd. Auditor Selection System'. It details the procedures, requirements, and regulations for selecting and appointing an accounting firm (auditor) for the company. The content includes legal references, internal governance procedures, evaluation criteria, and supervisory responsibilities related to auditor selection and replacement. There is no financial data, audit opinions, or financial statements included. The document is a policy or governance document about auditor appointment processes rather than an audit report or annual report. It does not announce or publish a report but sets internal rules and procedures. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-13 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System' and is issued by 海创药业股份有限公司 (Haichuang Pharmaceutical Co., Ltd.). It is a detailed internal policy document outlining the principles, definitions, decision-making authority, pricing principles, approval procedures, and disclosure requirements for related party transactions. The document references relevant laws and stock exchange rules, but it is not a financial report, earnings release, or announcement. It is a governance-related document detailing internal rules and procedures for managing related party transactions. Therefore, it fits best under Governance Information (CGR). The document length is 8287 characters, indicating it is a full policy document rather than a brief announcement or summary.
2025-08-13 Chinese
募集资金管理制度
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and is issued by a company. It details the rules and procedures for the management, use, supervision, and reporting of funds raised by the company through stock issuance or other equity securities. The content includes detailed governance and operational guidelines for the handling of raised funds, including storage, usage, changes in investment direction, supervision, and reporting requirements. It references regulatory frameworks and internal company rules. This document is a policy or governance document related to capital management rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, earnings data, voting results, or transaction details. It is not an announcement of a report but a formal internal management system document. Therefore, the most appropriate classification is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including capital management policies.
2025-08-13 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.